Long-acting drugs for hemophilia have emerged that could reduce the need for regular intravenous infusions of blood clotting agents. Treatments such as Biogen's Alprolix and Novo Nordisk's investigational drug N9-GP could help cut the cost of existing treatments, according to industry experts. Biotech companies such as BioMarin Pharmaceutical and Sangamo BioSciences are working on gene therapies that could enable people with hemophilia to make their own clotting factor.

Full Story:

Related Summaries